Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis

BACKGROUND: Single drug use has not achieved satisfactory results in the treatment of prostate cancer, despite application of increasingly widespread targeted therapeutics. In the present study, the combined impact of the mammalian target of rapamycin (mTOR)-inhibitor RAD001, the dual EGFr and VGEFr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wedel, Steffen, Hudak, Lukasz, Seibel, Jens-Michael, Makarević, Jasmina, Juengel, Eva, Tsaur, Igor, Waaga-Gasser, Ana, Haferkamp, Axel, Blaheta, Roman A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170298/
https://www.ncbi.nlm.nih.gov/pubmed/21867506
http://dx.doi.org/10.1186/1471-2407-11-375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170298/
https://www.ncbi.nlm.nih.gov/pubmed/21867506
http://dx.doi.org/10.1186/1471-2407-11-375

Ejemplares similares